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Abstract
Plasma fibrinogen is an acute phase protein playing an important role in the blood
coagulation cascade having strong associations with smoking, alcohol
consumption and body mass index (BMI). Genome-wide association studies
(GWAS) have identified a variety of gene regions associated with elevated plasma
fibrinogen concentrations. However, little is yet known about how associations
between environmental factors and fibrinogen might be modified by genetic
variation. Therefore, we conducted large-scale meta-analyses of genome-wide
interaction studies to identify possible interactions of genetic variants and smoking
status, alcohol consumption or BMI on fibrinogen concentration. The present study
included 80,607 subjects of European ancestry from 22 studies. Genome-wide
interaction analyses were performed separately in each study for about 2.6 million
single nucleotide polymorphisms (SNPs) across the 22 autosomal chromosomes.
For each SNP and risk factor, we performed a linear regression under an additive
genetic model including an interaction term between SNP and risk factor.
Interaction estimates were meta-analysed using a fixed-effects model. No genome-
wide significant interaction with smoking status, alcohol consumption or BMI was
observed in the meta-analyses. The most suggestive interaction was found for
smoking and rs10519203, located in the LOC123688 region on chromosome 15,
with a p value of 6.261028. This large genome-wide interaction study including
80,607 participants found no strong evidence of interaction between genetic
variants and smoking status, alcohol consumption or BMI on fibrinogen
concentrations. Further studies are needed to yield deeper insight in the interplay
between environmental factors and gene variants on the regulation of fibrinogen
concentrations.
Genome-Wide Interactions on Fibrinogen
PLOS ONE | DOI:10.1371/journal.pone.0111156 December 31, 2014 3 / 18
Introduction
Plasma fibrinogen is an acute phase protein playing an important role in the
blood coagulation cascade and is strongly associated with a variety of
environmental factors such as smoking status, alcohol consumption or obesity [1–
7]. Moreover, elevated fibrinogen concentrations indicate increased risks for
developing cardiovascular diseases [8–10]. Genetic studies reported substantial
relationships between specific genetic variants and fibrinogen concentrations [11–
17]; the heritability of plasma fibrinogen concentrations has been estimated to
range from 34% to 51% [11, 12, 18, 19]. Therefore, the regulation of fibrinogen
concentrations might be seen as a complex interplay between environmental and
genetic factors [20]. However, knowledge about potential interactions between
environmental factors such as cardiovascular risk factors and gene variants on
fibrinogen is still limited.
Smoking status, alcohol consumption and body mass index (BMI) are strong
determinants of fibrinogen concentrations [1–7]. A large meta-analysis showed
elevated fibrinogen concentrations in current smokers compared with non-
smokers; moreover, fibrinogen concentrations increased with the number of
cigarettes smoked per day showing a dose-related trend [7]. Similarly, elevated
fibrinogen concentrations have been reported in subjects with higher BMI values
[7]. For alcohol consumption, a lower mean fibrinogen concentration was
observed in subjects reporting current alcohol intake compared with subjects
reporting no alcohol intake [7]. All three factors represent behavioral risk factors
which are easy to assess and for which we hypothesized that gene-environment
interactions may modify individual risks enabling potentially targeted and
individualized preventive approaches.
Several family-based and genome-wide studies have reported associations of
specific gene regions with fibrinogen concentrations [11–17]. Recently, three large
genome-wide association studies (GWAS) including as many as 90,000
participants of European origin identified up to 24 strong association signals with
plasma fibrinogen concentration, among them one located in the fibrinogen b
chain (FGB) gene [15–17]. One of these analyses [17] was essentially based on the
same study population as in the present analyses.
However, little is known about whether the impact of smoking, alcohol
consumption, and BMI on fibrinogen concentrations is modified by specific gene
variants. Knowledge of such interactions might improve the understanding of the
underlying mechanism of fibrinogen synthesis and its regulation. Two candidate-
gene studies showed modifications in the association of smoking status and
fibrinogen concentration by the G/A-455 polymorphism (rs1800790) located at
the FGB gene [21, 22].
No genome-wide studies of effect modifications have been reported thus far for
fibrinogen concentrations. Therefore, the aim of the present study was to assess
potential gene-environment interactions (GxE) by smoking status, alcohol
consumption, and BMI on fibrinogen concentrations, using genome-wide data
from 22 studies with 80,607 subjects of European origin.
Genome-Wide Interactions on Fibrinogen
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Methods
Study population
The present study was carried out within the framework of the Cohorts for Heart
and Aging Research in Genomic Epidemiology (CHARGE) consortium which
combines data from several studies of participants of European origin conducted
in the United States and Europe [23]. Twenty-two studies comprising 80,607
participants provided results from their genome-wide interaction analyses for the
present investigation; an overview of these studies with basic information and
respective references is given in the online supporting information (S1 Methods
and S1 Table) All participants provided informed consent to use their DNA for
these analyses and all studies.
Fibrinogen measurements
Plasma fibrinogen concentrations were measured in 17 studies by a functional
method based on the Clauss assay and in five studies by an immunonephelometric
method and given in g/L [24, 25]. Fibrinogen concentrations were approximately
normally distributed in all studies and therefore analysed untransformed. More
details are given in the online supporting information (S1 Methods and S1 Table).
Assessment of smoking status, alcohol consumption and BMI
In all studies, smoking status and alcohol consumption were assessed by self-
reports from study participants; assessment of BMI was based on clinical
examination or self-report and described in kg/m2. For smoking status, current
smokers (‘‘smokers’’) were compared with a combined group of former smokers
and never-smokers (‘‘non-smokers’’). Former smokers were defined as not
smoking at time of examination in 19 studies; the remaining 3 studies set a
minimum cessation time before the examination which ranged between 30 days
and 3 years. For alcohol consumption, coding was ‘‘0’’ for no alcohol
consumption, ‘‘1’’ for alcohol consumption with less than 1 drink daily equivalent
to less than 10 g alcohol per day and ‘‘2’’ for alcohol consumption with 1 or more
drinks daily equivalent to 10 g alcohol or more per day. Information on smoking
status and BMI was available in all 22 studies and on alcohol consumption in 20
studies. The assessments of smoking status, alcohol consumption and BMI were
made at the same time as the fibrinogen measurements for all participants in all
studies.
Genotyping and imputation
Genotyping was conducted separately in each study using Affymetrix or Illumina
platforms and included from ,300,000 to ,1,000,000 genotyped single
nucleotide polymorphisms (SNPs). Genotype quality control and data cleaning
based on individual call rate, SNP call rate, and/or Hardy-Weinberg equilibrium
thresholds, and performed independently by each study.
Genome-Wide Interactions on Fibrinogen
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Genotyped data were imputed in each study separately to the ,2.6 million
SNPs identified in the HapMap II Caucasian (CEU) sample from the Centre
d’Etude du Polymorphisme Humain [26, 27].
More details about genotyping and imputation are given in the online
supporting information (S1 Methods and S2 Table).
Statistical analysis
Association of smoking status, alcohol consumption and BMI with fibrinogen
concentration
Associations of smoking status, alcohol consumption and BMI with fibrinogen
concentrations were assessed independently and separately in each study using
linear regression. Analyses were adjusted for age (linear) and sex as well as study-
specific covariates if required (see S1 Methods). Study-specific associations of
smoking status, alcohol consumption and BMI with fibrinogen concentration
were then meta-analysed using an inverse-variance weighted fixed-effect model.
Interaction between gene variants and smoking status, alcohol consumption
and BMI on fibrinogen concentration
Genome-wide analyses of the interaction between gene variants and smoking
status, alcohol consumption or BMI on fibrinogen concentration were performed
independently and separately in each study assuming an additive-genetic model
with an additive interaction. In all studies of unrelated individuals, linear
regression models with fibrinogen concentration as the outcome variable and the
SNP, the risk factor under consideration, and the interaction term ‘SNP x risk
factor’ were fit with adjustments for age (linear) and sex as well as study-specific
covariates if required (see S1 Methods). In family-based studies, linear mixed
effects models were applied to account for family correlations. Estimates of study-
specific genome-wide interactions were then meta-analysed applying inverse-
variance weighted fixed-effect models. To account for population stratification,
study-specific test statistics were corrected using the method of genomic control
[28]. SNPs with a low minor allele frequency (MAF) (,0.05) and a low
imputation quality (observed to expected variance ratio ,0.3) were omitted from
the meta-analyses.
The meta-analyses were performed using the software METAL developed for
genome-wide data [29]. To assess heterogeneity, the I2 index was computed for
each interaction estimate assuming that an I2 index around 25% or below
indicates no or low and around 50% moderate heterogeneity as suggested by
Higgins et al [30]. Genome-wide significance of interaction was defined as a p
value ,5.061028 for each of the three GxE analyses. Power analyses were
conducted using the R (version 3.0.2) pwr package.
Genome-Wide Interactions on Fibrinogen
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Results
Description of studies
The study population comprised a total of 80,607 participants of European
ancestry from 22 studies. Distributions of basic characteristics are provided for
each study in Table 1. Across the 22 studies, the average age ranged from 43.3 to
79.1 years and the percent of male participants ranged from 0 to 75.5%. Current
smoking behaviour was reported for 6.9 to 50.3% of the participants. No alcohol
consumption was reported for 5.8 to 54.9% of the participants and the mean BMI
ranged from 24.3 to 28.4 kg/m2. Mean fibrinogen concentration varied from 2.67
to 3.88 g/L.
Association of smoking status, alcohol consumption and BMI with
fibrinogen concentration
Strong significant associations of smoking status, alcohol consumption and BMI
with mean fibrinogen concentrations were observed in the vast majority of the 22
studies as can be seen in Fig. 1. Meta-analysis revealed mean differences in
fibrinogen concentrations of 0.163 g/L (95% CI 0.154 to 0.172, 8.56102280) for
current smokers compared with non-smokers, of -0.108 g/L (95% CI 20.113 to
20.102, 1.26102334) for one category increase of alcohol consumption (no,
,10 g/day, $10 g/day), and of 0.021 g/L (95% CI 0.020 to 0.022, p value
7.16102691) for one kg/m2 of BMI increase.
Interaction between gene variants and smoking status, alcohol
consumption and BMI on fibrinogen concentration – genome-wide
analyses
Overall
No genome-wide significant interactions with smoking status, alcohol con-
sumption and BMI were observed on fibrinogen concentration (Fig. 2). The
overall genomic inflation factors from the meta-analyses were 1.0174 for
interaction with smoking status, 0.9838 for interaction with alcohol consumption
and 1.0075 for interaction with BMI (see QQ plots in S1 Fig.). Exclusion of
studies with a genomic inflation factor .1.15 or ,1/1.15 (see S3 Table) did not
substantially alter these findings and revealed no genome-wide significant
interactions either. The heterogeneity of interaction estimates across studies was
rather weak. More than 85% of SNPs had an I2 index of 25% or less in all three
interaction analyses. The upper quartile of the I2 index value distribution was
15.5% for smoking, 16.1% for alcohol consumption and 15.5% for BMI analyses.
High-signal interactions
The Manhattan plot in Fig. 2 for smoking status (A) shows a peak on
chromosome 15 revealing suggestive evidence of an interaction with smoking
status for rs10519203, located in the LOC123688 region on chromosome 15, with
a p value of 6.261028 (Table 2). The difference in mean fibrinogen concentration
Genome-Wide Interactions on Fibrinogen
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between smokers and non-smokers was 0.048 g/L lower per copy of the A allele of
rs10519203. A forest plot providing the interaction estimates with smoking status
for each study and for the meta-analysis is given in S2 Fig. Heterogeneity was
estimated as I2 index545.4% indicating a moderate level of variation of the
interaction estimates across studies. The SNP rs10519203 alone was not
significantly associated with fibrinogen concentration in a ‘‘G’’ alone analysis (p
value 0.0005) performed by Sabater-Lleal et al. [17].
For alcohol consumption and BMI, the lowest p values were found for
rs11102001 in EPS8L3 on chromosome 1 (p value57.061027) and rs7120820 in
NELL1 on chromosome 11 (p value51.861026), see Table 2. In both cases, weak
heterogeneity was observed (I2 index#25%).
Table 1. Characteristics at the time of fibrinogen measurement by study.
Study
Sample
(N)
Age*
(years)
Male
sex (%)
Current
smokers (%)
No alcohol
consumption (%)
Alcohol
consumption
,10 g/day (%)
Alcohol
consumption
$10 g/day (%)
BMI (kg/
m2)
Fibrinogen*
(g/L)
ARIC 9,256 54.3 (5.7) 47.1 24.6 55.9 23.0 21.1 27.0 (4.8) 2.97 (0.61)
B58C 6,085 45.2 (0.4) 49.7 23.5 20.3 39.1 40.6 27.4 (4.9) 2.95 (0.60)
CARDIA 1,435 45.8 (3.3) 47.0 20.3 NA NA NA 25.4 (5.1) 3.18 (0.66)
CHS 3,242 72.3 (5.4) 39.0 11.3 46.0 38.5 15.5 26.3 (4.4) 3.15 (0.62)
CROATIA-Vis 761 56.6 (15.5) 41.7 27.9 43.0 19.2 37.8 27.1 (4.9) 3.58 (0.82)
FHS 2,797 54.1 (9.7) 45.5 18.5 29.8 57.9 12.3 27.4 (5.0) 3.05 (0.57)
HBCS 1,728 61.4 (2.9) 40.2 23.9 16.5 54.6 28.9 27.4 (4.5) 3.23 (1.04)
InCHIANTI 1,128 67.7 (15.1) 44.9 19.0 24.5 30.0 45.5 27.2 (4.1) 3.48 (0.75)
KORA F3 1,520 52.1 (10.2) 49.3 18.0 29.9 23.6 46.1 27.2 (4.1) 2.89 (0.66)
KORA F4 1,777 53.9 (8.9) 48.9 20.0 24.5 29.9 45.6 27.7 (4.6) 2.67 (0.60)
LBC1921 466 79.1 (0.6) 42.1 6.9 23.2 56.9 20.0 26.2 (4.1) 3.56 (0.85)
LBC1936 989 69.6 (0.8) 50.8 12.6 19.2 40.7 40.0 27.8 (4.4) 3.27 (0.63)
MARTHA 613 44.1 (14.2) 23.8 25.9 NA NA NA 24.3 (4.4) 3.36 (0.68)
NTR 2,343 47.1 (13.9) 35.8 16.8 5.8 74.2 20.0 25.4 (4.0) 2.78 (0.66)
ORCADES 686 53.7 (15.3) 46.6 8.7 10.8 59.2 30.0 27.7 (4.9) 3.45 (0.81)
PROCARDIS-CL 3,490 61.9 (7.0) 75.5 50.3 37.3 33.7 29.0 28.4 (4.4) 3.88 (0.86)
PROCARDIS-Im 3,405 58.1 (8.9) 73.5 33.0 23.9 36.7 39.4 27.1 (4.2) 3.86 (1.00)
PROSPER 5,244 75.3 (3.3) 48.1 26.5 44.5 28.6 27.0 26.8 (4.2) 3.60 (0.74)
RS 2,068 70.4 (9.0) 35.0 23.5 18.1 51.6 30.3 26.4 (3.8) 2.81 (0.68)
SardiNIA 4,691 43.3 (17.6) 43.7 19.8 54.9 10.2 34.9 25.3 (4.7) 3.28 (0.66)
SHIP 3,807 48.7 (16.0) 48.4 31.5 34.3 19.1 46.6 27.2 (4.8) 2.98 (0.69)
WGHS 23,076 54.7 (7.1) 0 13.2 43.3 42.7 14.0 25.9 (5.0) 3.59 (0.78)
total 80,607
BMI: body mass index.
* Mean (standard deviation).
doi:10.1371/journal.pone.0111156.t001
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Interaction between gene variants and smoking status, alcohol
consumption and BMI on fibrinogen concentration - selected
candidate SNPs
The interaction of rs1800790 at the FGB locus and smoking status on fibrinogen
concentration (as it was shown in two candidate-gene approach studies
previously) was estimated with beta 50.029 in the present meta-analysis (p value
for interaction 0.006) indicating a 0.029 g/L higher level in mean fibrinogen
concentration per A allele copy in smokers compared with non-smokers
(Table 3). The I2 index of almost 60% indicated moderate heterogeneity.
Finally, we examined 24 signals previously shown to be associated with
circulating fibrinogen in genome-wide analysis in almost the same study
population [17] assuming a significance threshold of 0.0021 (Bonferroni
correction for 24 tests: 0.05/24). None of these candidates was significant at this
threshold in the present GxE meta-analyses. For smoking status, a suggestive
interaction was found for rs1800789 in the FGB gene on chromosome 4 (p value
for interaction 0.0028) revealing a 0.031 g/L higher difference in mean fibrinogen
concentration per A allele copy in smokers compared with non-smokers
(Table 3). This SNP represents almost the same signal as rs1800790 (r250.911,
D951.00) for which interactions with smoking was found previously and a similar
I2 index was estimated (see above).
For alcohol consumption and BMI, the lowest p values among the 24 signals
were observed for rs715 in CPS1 on chromosome 2 (p value50.0195) and for
rs10512597 in CD300LF on chromosome 17 (p value50.0049), see S4 and S5
Tables.
Discussion
Overall
The present study is the first to investigate interactions between smoking status,
alcohol consumption, and BMI and gene variants on fibrinogen concentrations
based on data from genome-wide interaction studies. Meta-analysing a
population of 80,607 participants of European ancestry drawn from 22 studies did
not identify any variant that modified the association of smoking status, alcohol
consumption and BMI with plasma fibrinogen concentrations with genome-wide
significance.
Fig. 1. Association of environmental factors with fibrinogen concentration (in g/L), adjusted for age
and sex. A) Forest plot for smoking status. The beta estimate with 95% confidence intervals indicates the
change in mean fibrinogen concentration (in g/L) by smoking status for each study and across all studies
(‘‘overall’’, estimated by meta-analysis). B) Forest plot for alcohol consumption. The beta estimate with 95%
confidence intervals indicates the change in mean fibrinogen concentration (in g/L) by alcohol consumption for
each study and across all studies (‘‘overall’’, estimated by meta-analysis). Alcohol consumption was assessed
only in 20 studies. C) Forest plot for BMI. The beta estimate with 95% confidence intervals indicates the
change in mean fibrinogen concentration (in g/L) by BMI for each study and across all studies (‘‘overall’’,
estimated by meta-analysis).
doi:10.1371/journal.pone.0111156.g001
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Association of smoking status, alcohol consumption and BMI with
fibrinogen concentration
Several studies have identified strong and significant associations of smoking
status, alcohol consumption and BMI with fibrinogen concentrations [1–7]. The
present study confirmed these associations and is in line with findings from a large
meta-analysis of 154,211 participants in 31 prospective studies conducted by the
Fibrinogen Studies Collaboration (FSC) which showed comparable estimates of
fibrinogen concentration differences in smokers compared to non-smokers and
for differences in BMI and alcohol consumption amounts [7]. These strong
associations of smoking status, alcohol consumption and BMI with fibrinogen
might be explained mainly by their relation with the acute phase reaction which
contributes to the regulation of the fibrinogen synthesis [1].
Interaction between gene variants and smoking status, alcohol
consumption and BMI on fibrinogen concentration – genome-wide
analyses
The present study found no evidence that the strong associations of smoking
status, alcohol consumption and BMI with fibrinogen concentrations were
significantly modified by any of the approximately 2.6 million polymorphisms
identified in the HapMap II Caucasian (CEU) sample. However, a peak on
chromosome 15 with suggestive evidence of an interaction with smoking status
was found for rs10519203 (p value for interaction 6.261028) which is located in
Fig. 2. Interaction of gene variants and environmental factors on fibrinogen concentration (in g/L), adjusted for age and sex. A) Manhattan plot for
smoking status. The horizontal axis denotes chromosome and position of each gene variant and the vertical axis gives the negative log10 of the p value for
interaction of each gene variant and smoking status on fibrinogen concentration (in g/L), estimated by meta-analyses. The dotted line denotes genome-wide
significance (5.061028). B) Manhattan plot for alcohol consumption. The horizontal axis denotes chromosome and position of each gene variant and the
vertical axis gives the negative log10 of the p value for interaction of each gene variant and alcohol consumption on fibrinogen concentration (in g/L),
estimated by meta-analyses. The dotted line denotes genome-wide significance (5.061028). Alcohol consumption was assessed only in 20 studies. C)
Manhattan plot for BMI. The horizontal axis denotes chromosome and position of each gene variant and the vertical axis gives the negative log10 of the p
value for interaction of each gene variant and BMI on fibrinogen concentration (in g/L), estimated by meta-analyses. The dotted line denotes genome-wide
significance (5.061028).
doi:10.1371/journal.pone.0111156.g002
Table 2. Interaction between gene variants and smoking status, alcohol consumption and BMI on fibrinogen concentration (in g/L) with lowest p value for
interaction.
Environmental factor
x SNP Chr Position A1* A2 % A1 Beta (SE) P value N studies Direction** I2 index
Smoking status x
rs10519203
15 76601101 A G 64.8 20.048 (0.009) 6.261020-
8
22 ---+—+-+-------+-+--- 45.4%
Alcohol consumption
x rs11102001
1 110011733 A G 59.0 0.057 (0.012) 7.061020-
7
18 ++++-++?+++-+++++?++ 0.0%
BMI x rs7120820 11 21350435 T C 37.6 0.004 (0.009) 1.861020-
6
21 ++++-++—+-+-+---++?++ 20.2%
BMI: body mass index, SNP: single nucleotide polymorphism, Chr: chromosome, SE: standard error.
* Allele 1 is effect allele, ** The order of studies under ‘‘direction’’ refers to the order of studies in Table 1.
doi:10.1371/journal.pone.0111156.t002
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the LOC123688 region. The effect on fibrinogen level by smoking status was lower
per copy of the A allele (major allele) indicating that fibrinogen regulation by
tobacco exposure might be attenuated depending on the genotype of rs10519203.
Table 3. Interaction with smoking status for association with fibrinogen concentration (in g/L) in SNPs with previously reported interactions (Green et al.
1993; Thomas et al. 1996) or among SNPs associated with circulating fibrinogen (Sabater-Leal et al. 2013).
SNP Chr Position A1* A2 % A1 Beta (SE) P value N studies Direction** I2 index
Significant interaction according to Green et al. (1993) and Thomas et al. (1996):
rs1800790 4 155703158 A G 23.2 0.029 (0.011) 0.0062 22 +++++---++-+++-++—
+—
59.2%
Significant SNPs according to Sabater-Leal et al. (2013):
rs1938492 1 65890417 A C 62.1 0.017 (0.009) 0.058 22 ++-+---+-+++-+-+++—
++
0.0%
rs4129267 1 152692888 T C 39.1 20.004 (0.009) 0.614 22 +-+-+-++—+++++---++-
+
43.9%
rs10157379 1 245672222 T C 62.3 0.008 (0.009) 0.386 21 ------+++++-++++++-
?++
0.0%
rs12712127 2 102093093 A G 40.6 0.009 (0.009) 0.286 22 ++-++-++—+-++-
+++++—
0.0%
rs6734238 2 113557501 A G 58.6 20.005 (0.009) 0.561 22 +---+++-+-+-+—+-+-+-+ 0.8%
rs715 2 211251300 T C 68.0 20.007 (0.011) 0.501 17 -?+?-+—?+—?+-+—
+?+-
0.7%
rs1476698 2 241945122 A G 64.5 0.008 (0.009) 0.357 22 ++------+---+—++++-++ 34.9%
rs1154988 3 137407881 A T 78.1 20.013 (0.010) 0.194 22 -----+-++++---+—+-+-+ 0.0%
rs16844401 4 3419450 A G 7.5 0.017 (0.020) 0.392 18 —??+?-+++++—+++-
+?-+
1.0%
rs1800789 4 155702193 A G 21.1 0.031 (0.011) 0.0028 22 +++++---++-++—++----- 61.1%
rs11242111 5 131783957 A G 5.7 0.051 (0.033) 0.124 9 +??+?+?+?-?++?-
????+??
30.0%
rs2106854 5 131797073 T C 20.8 20.004 (0.011) 0.737 22 ---------+-+++++-+++++ 0.0%
rs10226084 7 17964137 T C 51.9 20.008 (0.009) 0.374 22 -++++---+---+-++---+— 0.0%
rs2286503 7 22823131 T C 36.1 20.013 (0.009) 0.131 22 +-+-++++++—+-+----
+—
0.0%
rs7464572 8 145093155 C G 59.7 20.004 (0.009) 0.672 19 +?++----?-++?-+----+-+ 0.0%
rs7896783 10 64832159 A G 48.4 20.014 (0.008) 0.094 22 -+-++—++-----+----+— 0.0%
rs1019670 11 59697175 A T 35.8 20.009 (0.009) 0.345 22 +---++++++---+----+--- 0.0%
rs7968440 12 49421008 A G 64.0 0.003 (0.009) 0.855 22 +-+-+----+----++++—++ 52.0%
rs434943 14 68383812 A G 31.7 20.002 (0.010) 0.884 21 -----+-++++----++++?++ 0.0%
rs12915708 15 48835894 C G 30.6 20.003 (0.009) 0.776 22 -+—++---+-++----+-+— 20.7%
rs7204230 16 51749832 T C 69.7 0.008 (0.010) 0.447 19 +?-++—+?+—?-+++++-
++
0.0%
rs10512597 17 70211428 T C 17.9 20.008 (0.012) 0.490 21 ----+-+—+-+—+-
+++?++
0.0%
rs4817986 21 39387382 T G 27.9 20.025 (0.010) 0.011 20 —?+---+-----++---+?— 12.8%
rs6010044 22 49448804 A C 79.5 0.005 (0.012) 0.669 21 +—++++---++++—?-
++++
0.0%
SNP: single nucleotide polymorphism, Chr: chromosome, SE: standard error.
* Allele 1 is effect allele, ** The order of studies under ‘‘direction’’ refers to the order of studies in Table 1.
doi:10.1371/journal.pone.0111156.t003
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A strong association of genetic variants in the LOC123688 region with lung cancer
has been reported recently [31–33]. One of these variants, rs8034191, was in
complete linkage disequilibrium with rs10519203 (r251, D951). Interestingly,
Truong et al. found that these variants were associated with significantly increased
lung cancer risk per copy of their minor allele in former or current but not in
never smokers [33].
Interaction between gene variants and smoking status, alcohol
consumption and BMI on fibrinogen concentration - selected
candidate SNPs
Two previous studies with a candidate-gene approach reported interactions
between the G/A-455 polymorphism at the FGB gene (rs1800790) and smoking
status on fibrinogen concentration in samples of healthy men; however, these
studies reported contradictory findings [21, 22]: whereas, in 86 healthy men,
fibrinogen concentrations were significantly higher per copy of the A allele in
smokers only [21], the opposite was true in 482 healthy middle-aged men with
significant associations only in non-smokers [22]. The present meta-analyses
could confirm the findings of an association only in smokers [21] albeit with a
sample size more than 200 times larger.
Several studies have identified strong associations of specific variants with
fibrinogen levels; one of these was in the fibrinogen b chain (FBG) gene [15–17].
A very recently performed meta-analysis conducted also within the framework of
the CHARGE consortium and comprising almost the same study population as
the present investigation revealed 24 independent signals in 23 loci being
significantly associated with fibrinogen concentration [17]. The present GxE
meta-analyses indicated no significant modifications of the associations of
smoking status, alcohol consumption and BMI with fibrinogen concentration.
Strengths and limitations
The present study was restricted to genetic variants with a minor allele frequency
of at least 5%. Analyses for variants with a lower MAF produced an excess of small
p values which were likely due to a poor approximation of true null distribution
of the test statistics by the normal distribution. It is possible, however, that there
may be significant interactions for rare variants which could be detected in studies
with improved approximations or with even larger sample sizes. Moreover, the
three determinants of fibrinogen were employed in commonly used categoriza-
tions across all studies; however, other definitions (e.g. never smokers versus ever
smokers, other cut-off values than 10 g/day for alcohol consumption or
categorized BMI) might yield significant interactions. Finally, we observed
heterogeneity in covariate distribution and effect estimates which may affect our
findings.
The present study is the first genome-wide interaction study aimed to detect
interactions between environmental factors and gene variants on fibrinogen
Genome-Wide Interactions on Fibrinogen
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concentration. Its strength relies on the large numbers of studies and participants
which was confirmed by a power analysis: If we assume a study population with a
prevalence of exposed of $20% (e.g. smokers), a SNP with a MAF of $0.05, and
an interaction of $0.1 meaning that the difference in mean fibrinogen
concentration between exposed and non-exposed participants is at least 0.1 g/L
higher per one copy of the minor allele, the power to detect an interaction would
be greater than 90% based on 80,000 participants and a significance level of
5.061028.These estimations indicate that the power of our study is large enough
to detect genome-wide relevant interactions between SNPs and smoking, alcohol
consumption and BMI on fibrinogen concentration.
Conclusions
The present large genome-wide interaction analyses including 22 studies
comprising 80,607 subjects of European ancestry did not identify significant
interaction of gene variants and smoking status, alcohol consumption or BMI on
fibrinogen concentrations. The strong associations of these three variables with
fibrinogen are not modified substantially by any of the 2.6 million common
genetic variants analysed in this study. Suggestive evidence of an interaction could
be found for smoking status with a fibrinogen-SNP association in smokers and
but not in non-smokers. Further studies are needed to yield deeper insight in the
interplay between environmental factors and functional genomics on the
regulation of fibrinogen concentrations.
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